<DOC>
	<DOCNO>NCT00657059</DOCNO>
	<brief_summary>A multi-center , randomize , control clinical trial evaluate short-term long-term efficacy safety mycophenolate mofetil ( MMF ) reduce proteinuria preserve renal function patient IgAN pre-treated ( continue treat ) angiotensin II receptor blocker ( ARB ) , compare corticosteroid .</brief_summary>
	<brief_title>Mycophenolate Mofetil ( MMF ) Patients With IgA Nephropathy ( IgAN )</brief_title>
	<detailed_description>There four phase study subject . Phase 1 screen phase . During phase potential subject evaluate determine he/she eligible study . Phase 2 ARB lead-in phase last three month . Phase 3 intervention phase . Each subject randomly receive 12 month treatment study drug ( MMF , prednisone MMF plus prednisone ) Phase 4 following-up phase . All patient follow 3 year study drug stop .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Willingness sign inform consent Age:14~60 year , regardless gender Clinical evaluation renal biopsy diagnostic IgAN , exclude secondary IgAN . Renal histological criterion define Lee 's glomerular grading system . 1 g/day &lt; = proteinuria &lt; 3.5 g/day , UPr/Cr ratio ≥ 0.6 ( male ) ≥ 0.8 ( female ) take ARB eGFR ≥ 40 mL/min/1.73 m2 Inability unwillingness sign inform consent Inability unwillingness meet scheme demand raise investigator Rapidly progressive nephritic syndrome acute renal failure , include rapidly progressive IgAN ( IgAN rapid decline renal function characterize histologically necrotizing vasculitis crescent formation≥30 % ) necessitating use immunosuppressive agent . Secondary IgAN systemic lupus erythematosus , HenochSchonlein purpuric nephritis hepatitis B associate nephritis est GFR &lt; 40 mL/min/1.73m2 Malignant hypertension difficult control oral drug Cirrhosis , chronic active liver disease . History significant gastrointestinal disorder ( e.g . severe chronic diarrhea active peptic ulcer disease . ) Any Active systemic infection history serious infection within one month entry know infection HIV , hepatitis B , hepatitis C. Other major organ system disease ( e.g . serious cardiovascular disease include congestive heart failure , chronic obstructive pulmonary disease , asthma require oral steroid treatment central nervous system disease ) Malignant tumor ( except fully cure basal cell carcinoma ) Absolute neutrophil count ＜ 1500／mm3 , absolute platelet count ＜75000／mm3 hematocrit ( Hct ) &lt; 28 % ( anemic subject may reevaluate anemia treat . ) Known allergy , contraindication intolerance MMF , corticosteroid ACEI/ARB . Pregnancy breast feeding time entry unwillingness comply measure contraception Current exposure MMF azathioprine . In case current treatment oral steroid ACEI/ARB , entry permit corticosteroid ACEI/ARB stop 2 week . Current recent ( within 30 day ) exposure investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>IgA nephropathy</keyword>
	<keyword>mycophenolate mofetil</keyword>
</DOC>